Nucleic acid drugs have the potential to treat neuromuscular and metabolic diseases where small molecule drugs have failed.
Enleofen Bio will receive more than US$1 billion in earnout payments from Boehringer Ingelheim’s acquisition of worldwide exclusive rights to its preclinical interleukin-11 platform.
With the creation of two new research centres and a billion-dollar fund in China, AstraZeneca looks set to make waves in biomedical research and healthcare in Asia.
The GalaXi® platform grants researchers access to billions of virtual molecules, paving the way for faster drug discovery and development.
The joint venture has resulted in the independent company JAGUAHR Therapeutics, which will focus on developing aryl hydrocarbon receptor antagonists for cancer treatment.
Tagrisso, a small molecule inhibitor drug, has been approved in China as a first-line treatment for patients with non-small cell lung tumors bearing specific mutations.